Loading
companiesCompany
Aadi Bioscience
Aadi Bioscience won approval for Fyarro, the albumin-bound sirolimus that treats the rare sarcoma PEComa, then sold it and renamed itself Whitehawk Therapeutics to develop antibody-drug conjugates.
Also called: Whitehawk TherapeuticsAadi Bioscience, Inc.NASDAQ:AADI
Overview
Aadi Bioscience developed nab-sirolimus (Fyarro, ABI-009), an mTOR inhibitor bound to albumin nanoparticles for better tumour delivery. The FDA approved it in November 2021 for malignant perivascular epithelioid cell tumour, the first drug for that sarcoma; the PRECISION 1 trial tested it in tumours with TSC1 or TSC2 alterations. In 2025 Aadi sold Fyarro to Kaken Pharmaceutical, in-licensed three antibody-drug conjugates from WuXi Biologics and Hangzhou DAC, and became Whitehawk Therapeutics.
Headquarters
Los Angeles, California, US
Scorecard
All companies#304of 1244 companies, score 13
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +2
1 approved, 0 in phase 3, 0 earlier, 1 targets, 1 registry studies. Formula on the scorecards page.
Type
Biotech · NASDAQ:AADI
Stage
Public
Website
ApprovedAlbumin-bound mTOR inhibitor (intravenous)
Sirolimus protein-bound particles · Fyarro
Fyarro is an infusion of the transplant drug sirolimus packaged in albumin particles. It is the first approved treatment for malignant PEComa, a rare soft-tissue tumour driven by loss of the TSC genes.
Similar pages
- Key paperAMPECT: nab-sirolimus for malignant perivascular epithelioid cell tumours
Shares AMPECT, Sirolimus protein-bound particles.
- TargetTSC1
Shares Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1), Sirolimus protein-bound particles.
- TargetTSC2
Shares Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1), Sirolimus protein-bound particles.
- CancerPerivascular epithelioid cell tumour (PEComa)
Shares AMPECT, Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1), Sirolimus protein-bound particles.
- TargetmTOR
Shares AMPECT, Sirolimus protein-bound particles.
drugs
ApprovedAlbumin-bound mTOR inhibitor (intravenous)
Sirolimus protein-bound particles · Fyarro